Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.
about
Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usageBacterial Infections in Hematopoietic Stem Cell Transplant RecipientsIsolation and characterization of φkm18p, a novel lytic phage with therapeutic potential against extensively drug resistant Acinetobacter baumanniiComparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill PatientsMultiple lung abscesses due to acinetobacter infection: a case reportTigecycline use in serious nosocomial infections: a drug use evaluation.Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter InfectionsInfections Caused by Acinetobacter baumannii in Recipients of Hematopoietic Stem Cell Transplantation.In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa.Drug treatment for multidrug-resistant Acinetobacter baumannii infections.Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis.Hospital acquired antibiotic-resistant acinetobacter baumannii infections in a 400-bed hospital in Tehran, Iran.Risk Factors and Predictors of Mortality in Critically ill Children with Extensively-Drug Resistant Acinetobacter baumannii Infection in a Pediatric Intensive Care Unit.[Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].Neutropenia exacerbates infection by Acinetobacter baumannii clinical isolates in a murine wound model.Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infectionAcinetobacter baumannii Septicemia in a Recipient of an Allogeneic Hematopoietic Stem Cell Transplantation.In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogensEmergence of Multidrug Resistance and Metallo-beta-lactamase Producing Acinetobacter baumannii Isolated from Patients in Shiraz, IranIn vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.Molecular Epidemiology of Multi-Drug Resistant Acinetobacter baumannii Isolated in Shandong, China.Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization.Newer developments in the treatment of Gram-positive infections.Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.Nosocomial infections in pediatric population and antibiotic resistance of the causative organisms in north of iran.Treatment options for multidrug-resistant nonfermenters.Resistant pathogen-associated skin and skin-structure infections: antibiotic options.Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance.Efficacy and safety of tigecycline: a systematic review and meta-analysis.Surveillance and management of multidrug-resistant microorganisms.Therapeutic options for Acinetobacter baumannii infections: an update.Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections.Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence.Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Greece: an extended review (2000-2015).In vitro activity of tigecycline against Acinetobacter baumannii isolates from a teaching hospital in Malaysia.Acinetobacter Infections among Adult Patients in Qatar: A 2-Year Hospital-Based Study.Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012).Molecular Study of Acinetobacter baumannii Isolates for Metallo-β-Lactamases and Extended-Spectrum-β-Lactamases Genes in Intensive Care Unit, Mansoura University Hospital, Egypt.
P2860
Q21560993-9589432D-A6D8-4937-A45F-19159971B260Q26799576-84519A65-6B8E-4FC2-8A0F-B50EED4F3745Q28484243-F8DBF4D1-14CF-41F4-8095-15E1D9308B24Q28550492-F4006E69-48B6-4FEB-B7D8-C2B328128E62Q33580588-D78DB093-9232-4E53-92D5-F5E23511FCF5Q33709972-812526FB-E8B7-4222-9344-92F8D37C0CA3Q33732524-7804F63E-0C2A-4CC5-9B45-2A7A9DCF9A9BQ33892585-09554D09-5CE4-4BE3-906C-320539D9FABEQ34255044-3C7E74B1-BB43-4B09-A586-5FF70855E425Q34601684-82F82D04-DAF0-4A7D-BCF1-0FDBEC060D35Q34803735-7096AD87-2500-40C5-8BF1-DC7B577C212CQ35101242-897462F8-54A5-4FAC-9859-9C9DD5D9AD8EQ35127885-D2E11637-DEA3-4B18-B0B9-EFABE556BFB2Q35176678-A48AFB60-E191-48FE-B1CC-911542FFBF44Q35619094-26A35B7C-5358-406D-9D39-60242263AAA9Q36167957-24F0D058-85C5-4565-9F68-56C44991A0F7Q36178130-C10F4EDB-4999-41D0-ABF8-25FF58CE29D4Q36417501-37923A25-E64B-4DE1-8412-CA2D70BFD62BQ36465442-8A9DAFD6-DAC5-4523-B83C-B755A0BA84D5Q36854025-1ABB7A20-59F8-4602-8F14-065278B2DED9Q37045888-59DE31A0-783C-4C19-94DA-FA593C75E32AQ37220041-7B2F1D79-3789-41C1-981A-C2FFE42B2A07Q37355116-C6BE62F4-9390-4B33-A508-8DC6CD322812Q37608268-9FA71754-3D29-424E-84C4-4385BE109059Q37636151-4B56C132-83E2-4200-BEEB-F95EA1863DBFQ37656243-37581238-B16F-4C38-A333-D8D458C735B4Q37663353-836D59B1-9F0E-472B-86A4-A86FB1ADA13BQ37700555-E9D3612C-39E6-4515-ABEB-822B33634940Q37785546-7BEE239A-3E17-43A4-A3A0-6F46B1A93C16Q37869910-1A0A1931-F413-4B8C-A79D-A88D26A9BBEDQ37891606-55C2B75E-092C-47D2-84A9-E5FC5A22CAEEQ37912231-E5FE22AD-C2B0-400E-A410-F4DD8CC2E46FQ38049332-B3011E21-60A6-451D-BF6C-79D6BC94B357Q38088261-C76F155E-DC5B-457E-B2D0-376CC3BFE2ADQ38147851-80355D10-543B-4B61-A8E9-61FAA728C04AQ38672110-9F5EFF5B-9610-42E3-AF11-68C90300449AQ38971801-D058880D-9DFA-4C3F-8731-20745CD89C89Q39586230-659FD990-6389-4A05-BD04-623ED9C588AAQ39683665-3A39D905-6BDB-4E2C-8E6C-2FFDD3113E72Q40190095-931EFFCE-37D8-493C-BD4A-31EEE41400E4
P2860
Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tigecycline for the treatment ...... ew of the scientific evidence.
@en
Tigecycline for the treatment of multidrug-resistant
@nl
type
label
Tigecycline for the treatment ...... ew of the scientific evidence.
@en
Tigecycline for the treatment of multidrug-resistant
@nl
prefLabel
Tigecycline for the treatment ...... ew of the scientific evidence.
@en
Tigecycline for the treatment of multidrug-resistant
@nl
P356
P1476
Tigecycline for the treatment ...... ew of the scientific evidence.
@en
P2093
Iosif Kelesidis
Theodore Kelesidis
P356
10.1093/JAC/DKN165
P407
P577
2008-04-24T00:00:00Z